PAUL NEUMAN: Open Payments
NPI 1568947687 · APOPKA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$567 in 17 payments from 8 companies in 2025. Trend: 2023 $1,149 · 2024 $713 · 2025 $567
Food & beverage: $478Education: $89
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $138 |
| Novartis Pharmaceuticals Corporation | 5 | $123 |
| Janssen Biotech, Inc. | 1 | $89 |
| Lilly USA, LLC | 1 | $78 |
| ABBVIE INC. | 3 | $70 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Amgen Inc. | 1 | $21 |
| UCB, Inc. | 1 | $18 |
Products named: DUPIXENT, TREMFYA, COSENTYX, TALTZ, SKYRIZI, NUZYRA, OTEZLA, Bimzelx.
Industry payments across FL — which companies pay providers there.
